Built on BactPac™
A first-in-class pipeline
We are developing a first-in-class pipeline addressing three therapeutic areas: cancer, respiratory, and genetic diseases
Targeting severe diseases faces the challenge of finding truly effective delivery methods. SiVEC steps in as the knowledgeable guide, offering a revolutionary drug delivery system called BactPac. With this, medicines can be directed precisely where they're needed most. SiVEC invites biotech and pharma companies to join them in this mission, promising a future where treatments are safer, more effective, and can conquer even the toughest diseases.
SiVEC is also pursuing additional discovery programs that are not included in the following pipeline table.
Cancer
SVC-KRAb™
Using the BactPac platform, SiVEC has developed SVC-KRAb™, a first-in-class live pan-RAS biotherapeutic that targets cancer-driving RAS proteins across mutations and isoforms. SVC-KRAb™ is widely applicable to a broad patient population due to its recalcitrance to specific RAS mutations, revolutionizing the treatment of RAS-mutant cancer. We have engineered our bacteria to express and deliver a single-domain antibody (nanobody) that broadly targets mutant RAS. This cancer therapeutic targets RAS mutations in pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC), among others.
ADVANTAGES of SVC-KRAb™
• BactPac produces the cancer-targeting therapeutic during manufacturing
• BactPac targets and infiltrates tumors
• BactPac delivers its cargo intracellularly to inhibit cell-autonomous signaling
IN VIVO EFFICACY of SVC-KRAb™
In vivo mouse studies of SVC-KRAb demonstrate its efficacy in targeting oncogenic KRAS mutations. SVC-KRAb was tested in a human cancer cell xenograft model using cells carrying a KRAS G12S mutation. The data (below) revealed up to an 80% reduction in tumor volume following intravenous (IV) injection of SVC-KRAb compared to untreated controls.. This highlights SVC-KRAb’s potential in treating KRAS-driven cancers, including those with non-G12C KRAS mutations.
BEST IN CLASS POTENTIAL: SVC-KRAb outperforms leading clinical pan-RAS inhibitor
SVC-KRAb demonstrates strong benchmarking against RMC-6236 (daraxonrasib, Revolution Medicines’ lead pan-RAS small molecule inhibitor). In KRAS(G12S) lung cancer cells (A549) and HRAS(G12V) bladder cancer cells (T24), SVC-KRAb significantly reduces cell viability, achieving effects comparable to or stronger than small-molecule inhibition. These results highlight the potential of SVC-KRAb as a differentiated therapeutic modality capable of targeting multiple oncogenic RAS mutations across tumor types.
SVC-Survivin™
SVC-Survivin is a therapeutic developed using the BactPac™ platform. SVC-Survivin targets the survivin protein, which is commonly expressed in cancer cells and inhibits apoptosis. By blocking Survivin’s anti-apoptotic effect,, SVC-Survivin enhances the efficacy of standard chemotherapies, potentially increasing their effectiveness while reducing associated side effects. This therapy is intended for use alone or in combination with chemotherapy to improve patient outcomes.
ADVANTAGES of SVC-Survivin™
• SVC-Survivin enhances efficacy of front-line chemotherapy
• BactPac produces the cancer-targeting therapeutic during manufacturing
• BactPac targets and infiltrates tumors
• BactPac delivers its cargo intracellularly to inhibit cell-autonomous signaling
Respiratory
SiVEC-IAV™
Individuals, especially those at high risk, dread the flu season and the hazard it poses. Enter SiVEC with SiVEC-IAV™, a pioneering antiviral solution that can be easily inhaled or sprayed to offer rapid and broad protection against the flu. Not only does it work against a wide range of strains, but it's also easy to use, store, and produce. SiVEC encourages everyone to embrace this revolutionary approach to flu treatment and prevention, ensuring a flu season that's more manageable and less threatening.
SiVEC-IAV™ is the first inhaled live biotherapeutic antiviral. SiVEC-IAV is an siRNA therapeutic that is delivered to the respiratory tissues to stop influenza virus infection. The BactPac platform has been engineered to express shRNA molecules targeting conserved regions in all type A influenza viruses, providing fast-acting broad anti-influenza activity against seasonal and pandemic flu.
ADVANTAGES of SiVEC-IAV™
• Inhaled or spray delivery to the respiratory tissues for rapid activity
• Non-invasive, safe and easy to use anytime and anywhere
• Broad protection against a wide range of influenza strains
• Activity against influenza viruses resistant to neuraminidase inhibitors
• Prevents development of antiviral resistance while maximizing protection
• Does not require cold-chain storage, scalable, rapid manufacturing
• Can be used in high-risk patients with complicated influenza